Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery

NCT ID: NCT00709436

Last Updated: 2012-01-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

250 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2011-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to evaluate the safety and analgesic efficacy of PMI-150 (intranasal ketamine) compared to placebo in patients with acute post-operative pain following orthopedic trauma, injury, or surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be randomly assigned to PMI-150 (intranasal ketamine) or placebo and will receive repeated doses and be assessed for safety and efficacy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain, Postoperative

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

PMI-150 (intranasal ketamine) at time 0 and specified time points thereafter.

Group Type EXPERIMENTAL

PMI-150 (intranasal ketamine)

Intervention Type DRUG

PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.

2

Placebo at time 0 and specified time points thereafter.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo (intranasal) at time 0 and scheduled times thereafter.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PMI-150 (intranasal ketamine)

PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.

Intervention Type DRUG

Placebo

Placebo (intranasal) at time 0 and scheduled times thereafter.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patient is scheduled for elective orthopedic surgery or procedure

Exclusion Criteria

* patient has received an investigational drug or participated in a clinical trial within 30 days or 5 half-lives (whichever is longer) of entering this study
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Javelin Pharmaceuticals

Role: STUDY_DIRECTOR

Javelin Pharmaceuticals

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jefferson Clinic

Birmingham, Alabama, United States

Site Status

Shoals Clinical Research

Florence, Alabama, United States

Site Status

Helen Keller Hospital

Sheffield, Alabama, United States

Site Status

Arizona Research Center

Phoenix, Arizona, United States

Site Status

Vertex Clinical Research

Bakersfield, California, United States

Site Status

California Clinical Research

Davis, California, United States

Site Status

CORE Orthopedic Medical Center

Encinitas, California, United States

Site Status

JDP Medical

Aurora, Colorado, United States

Site Status

Southeastern Center for Clinical Research

Atlanta, Georgia, United States

Site Status

Chesapeake Research Group

Pasadena, Maryland, United States

Site Status

The Ohio State University

Columbus, Ohio, United States

Site Status

Allegehny Pain Management

Altoona, Pennsylvania, United States

Site Status

University Orthopedics

State College, Pennsylvania, United States

Site Status

Comprehensive Pain Specialists

Hendersonville, Tennessee, United States

Site Status

Scott and White Memorial Hospital

Temple, Texas, United States

Site Status

Jean Brown Research

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KET-017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Post-op Ketamine Study
NCT03865550 UNKNOWN NA